H.c. wainwright reiterates buy rating for agile therapeutics (nasdaq: agrx), citing growing demand for twirla, a weekly low dose birth control patch

Princeton, nj / accesswire / july 5, 2023 / h.c. wainwright & co, reiterated its buy rating on agile therapeutics, inc. (nasdaq:agrx) this month, setting a price target of $12 per share.

AGRX Ratings Summary

AGRX Quant Ranking